Abstract
Introduction

Small-cell lung cancer (SCLC) constitutes 10-15% of total lung cancers (1, 2). It progresses aggressively but usually responds well to the initial chemotherapy, compared with non-small-cell lung cancer (NSCLC). In clinical practice, however, many SCLC patients have various comorbidities, which renders the standard platinum-based chemotherapy difficult to complete. Most elderly lung cancer patients have some comorbidities, including chronic obstructive pulmonary disease, ischemic heart disease and cerebrovascular disease (3). Even fit elderly patients experience a higher incidence of adverse effects and treatment-related deaths in clinical trials of SCLC (4-6). Thus, a standard treatment has not yet been established for elderly SCLC patients, especially when they have other diseases as well. End-stage renal disease (ESRD) is also common in Japan.
. There are also several reports of chemotherapy in SCLC or NSCLC patients on HD (9) (10) (11) . However, the present report is the first to describe successful chemotherapy in an SCLC patient on CAPD, partly because among the current renal replacement therapies in Japan and the United States, limited numbers of patients have elected to receive CAPD (7, 12) . Re n a l f u n c t i o n a n d t h e a r e a u n d e r t h e  c o n c e n t r a t i o n -t i me c u r v e ( AUC) o f c a r b o p l a t i 
Case Report
Clinical course
A 77-year-old Japanese man was diagnosed with limited disease small-cell lung cancer (LD-SCLC
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home 17 months after diagnosis. (13, 14) .
Hemodialysis
The dialyzer was FB-150 UB and its surface area was 1.5 m 2 . Dry weight was 65.0 kg with fluid removal of 150-250 mL, blood flow of 120 or 150 mL/min and dialysis solution flow 500 mL/min. Low molecular weight heparin was used as an anticoagulant. HD was started one hour after completing the administration of CBDCA and ETP on days 1 and 3, and dialysis time was 240 minutes. The dialysis was scheduled according to the previous report (9).
Pharmacokinetic analysis
Pharmacokinetic (PK) analysis of CBDC (total platinum) and ETP was carried out for each course. Blood samples were collected at one hour (before HD), 5 (after HD), 24, 49 (just before HD on day 3), 53 (just after HD on day 3) and 72 hours after the administration of anticancer agents on day 1. The platinum and ETP in the plasma were analyzed according to the methods of LeRey et al and Allen, respectively
The PK of CBDCA (total platinum) and ETP over the first course is shown in Fig. 2 (20) (21) (22) . Some studies showing that PCI caused no significant neurological toxicity did not include patients older than 70 years (23, 24 (Fig. 1) . Carboplatin or CBDCA-derived platinum is mainly cleared (70%) by renal excretion (16) . CAPD eliminates none or only 14-20% of the administered CBDCA during the first 24 hours (8, 9, 26 (11, 26) . In our patient, ETP concentrations were decreased as expected on the next day, although the exact clearance pathway was also undetermined. Second, the frequency of blood sampling was lower than in previous reports (8, 9, 16, 26 
